Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 32 (currently amended): A mixture of 108 different peptides, wherein each of said 108 different peptides comprises an amino acid sequence according to the following formula ("Formula II"; SEQ ID NO: 39):

 $QTX^1TVGGQASX^2QASSLTX^3LFSX^4GX^5KQN$, wherein X^1 is either H or T;

 $\overline{X^2}$ is either H or R;

 X^3 is either S, G, or R;

X⁴ is either P, L or Q; and

 X^5 is either A, S, or P.

Claim 33 (currently amended): A composition comprising a plurality of <u>different</u> peptides, wherein each of said <u>plularity of different</u> peptides comprises an <u>a different</u> amino acid sequence provided by Formula II (SEQ ID NO: 39):

QTX¹TVGGQSX²QASSLTX³LFSX⁴GX⁵KQN, wherein

X¹ is either H or T;

 X^2 is either H or R;

 X^3 is either S, G, or R;

 X^4 is either P, L or Q; and

 X^5 is either A, S, or P.

Claim 34 (currently amended): A composition according to claim 33, wherein said composition consists of 2 to about 10 of said different peptides having said amino sequence provided by Formula II (SEQ ID NO: 39).

Claim 35 (previously presented): A composition according to claim 33, further comprising at least one peptide selected from the group consisting of:

- G31 TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6)
- F78 QTHTTGGQAGHQAHSLTGLFSPGAKQN (SEQ ID NO: 19)
- R9 QTTVVGGSQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10)
- D6 QTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3)
- M122 OTTTTGGSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 23); and
- H1 OTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 20).

Claim 36 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 10, 19, 20, and 3 ("MIX1").

Claim 37 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 23 and 6 ("MIX2").

Claim 38 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 6, 19, 10, 3, 23 and 20 ("MIX3").

Claim 40 (currently amended): A composition according to claim 33 wherein each of said plurality of different peptides consists of said sequence and a hepatitis C virus E2/NS1 protein with the peptide in the HVR1 position.

Claim 43 (previously presented): A composition according to claim 33 wherein said composition further comprises a pharmaceutically acceptable excipient.

Claim 44 (previously presented): A composition according to claim 43 wherein said composition further comprises an adjuvant.

Claim 45 (currently amended): A peptide comprising an amino sequence provided by Formula II (SEQ ID NO: 39):

QTX¹TVGGQASX²QASSLTX³LFSX⁴GX⁵KQN, wherein

X¹ is either H or T;

 X^2 is either H or R;

X³ is either S, G, or R;

X⁴ is either P, L or Q; and

X⁵ is either A, S, or P.

Claim 46 (currently amended): A peptide comprising an amino sequence provided by Formula I (SEQ ID NO: 1):

 $X^{1} T X^{2} X^{3} X^{4} G G X^{5} X^{6} X^{7} X^{8} X^{9} X^{10} X^{11} X^{12} L X^{13} X^{14} L F X^{15} X^{16} G X^{17} X^{18} Q X^{19}$ wherein,

 X^{l} is Q or T,

 X^2 is H, T or R,

 X^3 is V or T,

 X^4 is T or \overline{V} ,

 X° is S, V or Q,

 X^6 is A, Q or V,

 X^7 is A, G or S,

 X^8 is R or H,

 $\overline{X^9}$ is T, A or Q,

 X^{10} is T, A or V,

 X^{11} is S, H or R,

 X^{12} is G, S or R,

 X^{13} is T or V,

 \overline{X}^{14} is S, G or R,

 $\frac{X^{15} \text{ is S or R,}}{X^{16} \text{ is P, L, S or Q,}}$ $\frac{X^{17} \text{ is A, P or S,}}{X^{18} \text{ is S, K or Q, and}}$ $\frac{X^{19} \text{ is N or K.}}{X^{19} \text{ is N or K.}}$

Claim 47 (withdrawn): A peptide according to claim 46 with an amino acid sequence selected from the group consisting of:

2.11	QTHTVGGVQGRQAHSLTSLFSPGASQN (SEQ ID NO: 2)
D6	QTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3)
D18	QTHTTGGSASHQASGLTRLFSQGPSQN (SEQ ID NO: 4)
F63	QTHVVGGQQGRQVSSLVSLFSPGASQK (SEQ ID NO: 5)
G31	TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6)
L13	QTHTVGGSQAHAAHSLTRLFSPGSSQN (SEQ ID NO: 7)
M69	QTTVVGGSQARAAHGLVSLFSLGSKQN (SEQ ID NO: 8)
Z61	QTHVVGGVQGRQTSGLVGLFSPGSKQN (SEQ ID NO: 9)
R9	QTTVVGGSQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10)
B26	TTTTTGGQAGHQAHSLTSLFSPGASQK (SEQ ID NO: 11)
B22	QTHVVGGVQSHQTSGLTSLFSPGASQK (SEQ ID NO: 12)
B35	QTHTTGGVQGHQTSRLTSLFSPGPSQN (SEQ ID NO: 13)
D29	TTTVVGGQAAHQTHSLTSLFSPGAKQN (SEQ ID NO: 14)
D33	TTTTTGGQQSHTVHGLVGLFSPGSKQN (SEQ ID NO: 15)
E26	QTHTVGGVQAHTVRGLTSLFSPGSSQN (SEQ ID NO: 16)
F80	QTHTTGGQAGHTASSLTGLFSPGAKQN (SEQ ID NO: 17)
F19	QTTTVGGVASHQAHSLTGLFSPGAKQK (SEQ ID NO: 18)
F78	QTHTTGGQAGHQAHSLTGLFSPGAKQN (SEQ ID NO: 19)
H1	QTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 20)
L76	TTTTVGGQASHQTSSLTGLFSPGSKQN (SEQ ID NO: 21)
B24	TTTTVGGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 37)
M63	QTHTTGGVVSHQTRSLVGLFSPGPQQN (SEQ ID NO: 38)
M27	QTTTTGGVASHAAHRLTSLFSPGPQQK (SEQ ID NO: 22)

- M122 QTTTTGGSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 23)
- M129 QTTVVGGSAGHTASSLVGLFSPGSKQN (SEQ ID NO: 24)
- M119 TTTTVGGQASHTTSSLTGLFSPGSQQN (SEQ ID NO: 25)
- R5 QTHTTGGQASHQVSSLVSLFSPGAKQK (SEQ ID NO: 26)
- R6 TTTTTGGQVGHQTSGLTGLFSPGAQQN (SEQ ID NO: 27)
- R27 TTHVVGGSASHAVRGLTSLFSPGSSQN (SEQ ID NO: 28)

Claim 48 (withdrawn): A peptide of any of the following amino acid sequences:

- B14 QTTVTGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 29)
- B33 ATHATGGQAAHSTHSLTSLFSPGASQK (SEQ ID NO: 30)
- F81 QTHVTGGSAAHQTGGLTGLFSPGPKQN (SEQ ID NO: 31)
- B18 QTTVVGGQASHVSRLTGLFSPGSSQK (SEQ ID NO: 32)
- E19 TTHTGGQQAHTTSRLVSLFSPGASQK (SEQ ID NO: 36)
- L72 QTTTAAHTTSGLTGLFSPGAKQN (SEQ ID NO: 33)
- D20 QTHVTGVAGRQTSGLVSLFSPGSSQN (SEQ ID NO: 34)
- D30 QGGVQGHTTSSLVGLFSPGSQQN (SEQ ID NO: 35)

Claim 49 (withdrawn): A composition including a peptide selected from the group consisting of

- a) a peptide obtainable from a library as claimed in claim 1; and
- 2.11 QTHTVGGVQGRQAHSLTSLFSPGASQN (SEQ ID NO: 2); and
- D6 OTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3); and
- D18 QTHTTGGSASHQASGLTRLFSQGPSQN (SEQ ID NO: 4); and
- F63 QTHVVGGQQGRQVSSLVSLFSPGASQK (SEQ ID NO: 5); and
- G31 TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6); and
- L13 OTHTVGGSQAHAAHSLTRLFSPGSSQN (SEQ ID NO: 7); and
- M69 QTTVVGGSQARAAHGLVSLFSLGSKQN (SEQ ID NO: 8); and
- Z61 OTHVVGGVQGRQTSGLVGLFSPGSKQN (SEQ ID NO: 9); and
- R9 QTTVVGGSQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10); and
- B26 TTTTTGGQAGHQAHSLTSLFSPGASQK (SEQ ID NO: 11); and

B22 QTHVVGGVQSHQTSGLTSLFSPGASQK (SEQ ID NO: 12); and B35 QTHTTGGVQGHQTSRLTSLFSPGPSQN (SEQ ID NO: 13); and D29 TTTVVGGQAAHQTHSLTSLFSPGAKQN (SEQ ID NO: 14); and D33 TTTTTGGQQSHTVHGLVGLFSPGSKQN (SEQ ID NO: 15); and E26 QTHTVGGVQAHTVRGLTSLFSPGSSQN (SEQ ID NO: 16); and F80 QTHTTGGQAGHTASSLTGLFSPGAKQN (SEQ ID NO: 17); and F19 QTTTVGGVASHQAHSLTGLFSPGAKQK (SEQ ID NO: 18); and F78 QTHTTGGQAGHQAHSLTGLFSPGAKQN (SEQ ID NO: 19); and H1 QTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 21); and L76 TTTTVGGQASHQTSSLTGLFSPGSKQN (SEQ ID NO: 37); and B24 TTTTVGGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 38); and M63 QTHTTGGVVSHQTRSLVGLFSPGPQQN (SEQ ID NO: 22); and M27 QTTTTGGVASHAAHRLTSLFSPGPQQK (SEQ ID NO: 23); and M122 QTTTTGGSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 24); and M129 QTTVVGGSAGHTASSLVGLFSPGSKQN (SEQ ID NO: 25); and M119 TTTTVGGQASHTTSSLTGLFSPGSQQN (SEQ ID NO: 26); and R5 QTHTTGGQASHQVSSLVSLFSPGAKQK (SEQ ID NO: 27); and **R6** TTTTTGGQVGHQTSGLTGLFSPGAQQN (SEQ ID NO: 28); and R27 TTHVVGGSASHAVRGLTSLFSPGSSQN (SEQ ID NO: 29); and B14 QTTVTGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 29); and B33 ATHATGGQAAHSTHSLTSLFSPGASQK (SEQ ID NO: 30); and F81 QTHVTGGSAAHQTGGLTGLFSPGPKQN (SEQ ID NO: 31); and B18 QTTVVGGQASHVSRLTGLFSPGSSQK (SEQ ID NO: 32); and E19 TTHTGGQQAHTTSRLVSLFSPGASQK (SEQ ID NO: 36); and L72 QTTTAAHTTSGLTGLFSPGAKQN (SEQ ID NO: 33); and QTHVTGVAGRQTSGLVSLFSPGSSQN (SEQ ID NO: 34); and D20 D30 QGGVQGHTTSSLVGLFSPGSQQN (SEQ ID NO: 35).

Claim 50 (withdrawn): A composition including a plurality of peptides according to claim 49.

Claim 51 (withdrawn): A composition according to claim 50 including 2 to about 10 different peptides.

Claim 52 (withdrawn): A composition according to claim 50 wherein one or more of said peptides is in a fusion with additional amino acids.

Claim 53 (withdrawn): A composition according to claim 52 wherein said fusion includes HCV E2/NS1 protein with the peptide in the HVR1 position.

Claim 54 (withdrawn): A composition according to claim 53 wherein said fusion is included in a recombinant HCV.

Claim 55 (withdrawn): A composition according to claim 49 including at least one additional component.

Claim 56 (withdrawn): A composition according to claim 55 wherein said composition includes a pharmaceutically acceptable excipient.

Claim 57 (withdrawn): A composition according to claim 55 wherein said composition includes an adjuvant.

Claim 97 (currently amended): The composition of claim 33, wherein each of said <u>different</u> peptides consists of said <u>different</u> amino acid sequence.

Claim 98 (previously presented): The peptide of claim 45, wherein said peptide consists of said amino acid sequence.

Claim 99 (previously presented): The peptide of claim 46, wherein said peptide consists of said amino acid sequence.